Page
%P
-
Article
Open AccessNingetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is a common mutation type in acute myeloid leukemia (AML) and is usually associated with poor patient prognosis. With advancements in molecular...
-
Article
Open AccessSitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
Gilteritinib is the only drug approved as monotherapy for acute myeloid leukemia (AML) patients harboring FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation throughout the world. However, ...
